Objective Chronic kidney disease (CKD) is a serious disorder with significant public health impact. Identification of factors associated with risk of progression of kidney disease may help in earlier intervention in high risk groups. We investigated whether brachial pulse pressure (PP) was associated with 5-year changes in estimated glomerular filtration rate (eGFR) and incident CKD and whether type 2 diabetes modified these associations.
Objective Chronic kidney disease (CKD) is a serious disorder with significant public health impact. Identification of factors associated with risk of progression of kidney disease may help in earlier intervention in high risk groups. We investigated whether brachial pulse pressure (PP) was associated with 5-year changes in estimated glomerular filtration rate (eGFR) and incident CKD and whether type 2 diabetes modified these associations.
Methods In the population-based Australian Diabetes, Obesity and Lifestyle Study (AusDiab) 5554 individuals (5.8% with type 2 diabetes) who took part in the 5-year follow-up and had no CKD or microalbuminuria at baseline were included.
Results After adjusting for baseline age, sex, eGFR and use of blood pressure lowering medication, each baseline SD higher PP was associated with a decline in eGFR of 0.32 ml/min (p=0.006) and an odds ratio for CKD of 1.29 (95% CI: 1.09 to 1.53) in individuals without type 2 diabetes. In individuals with type 2 diabetes, eGFR declined by 1.10 ml/min (p=0.011) and the odds ratio for incident CKD was 1.94 (1.14 to 3.29). Similar associations with eGFR decline were observed with systolic blood pressure and incident CKD in individuals without type 2 diabetes. In individuals with type 2 diabetes, higher systolic blood pressure was only significantly associated with eGFR decline if the diastolic blood pressure was ≤ 70 mmHg (p for interaction between systolic and diastolic blood pressure: 0.033).
Introduction

Methods
Study population
The population based AusDiab is a prospective cohort study which began in 1999-2000. Initially, 11,247 adults, drawn from 42 randomly selected census collector districts across Australia, aged ≥ 25 years, participated at baseline (response rate 55.3% of those completing a household questionnaire). For the present prospective investigation, we used data from baseline (1999) (2000) and follow-up (2004-2005) examinations, of which methods and response rates are described in detail elsewhere.
12; 13 The study was approved by the International Diabetes Institute Ethics Committee and written informed consent was obtained from all participants.
Measurements
At baseline, SBP, DBP and heart rate in beats per minute were measured by using a Dinamap or a standard mercury sphygmomanometer with adjustments made as previously described.
14 PP was calculated as SBP minus DBP, and mean arterial pressure as 2/3 DBP plus 1/3 SBP. Hypertension was defined as DBP ≥ 90 mmHg, SBP ≥ 140 mmHg, and/or treatment with blood pressure lowering medication. Interviewer-administered quesInterviewer-administered questionnaires were used to assess age, sex, use of blood pressure, lipid or glucose lowering medication, prior CVD (angina, heart attack, and/or stroke), smoking, alcohol intake (drinks/week), exercise time (minutes/ week), salt intake (by means of a food frequency questionnaire) and socio-economic status (based on 4 education groups).
13
BMI and waist-hip ratio were defined and all participants except for those currently receiving treatment for diabetes or who were pregnant underwent a standard 75g OGTT and had glucose, total cholesterol, HDL cholesterol, triglycerides, urine creatinine, and urine albumin analysed as described earlier.
12;15 Type 2 diabetes was classified on the basis of plasma glucose levels or current treatment with insulin or oral glucose lowering medication.
Microalbuminuria (MA) was defined as an albumin:creatinine ratio (ACR) ≥ 2.5 mg/ mmol in men or ≥ 3.5 mg/mmol in women.
Serum creatinine was measured at baseline and follow-up by the modified kinetic Jaffe reaction, using the Olympus AU600 auto-analyser at baseline, and the Roche Modular at follow-up. Serum creatinine measurements were calibrated to the Isotope Dilution Mass Spectrometry (IDMS) method by re-assaying stored subsamples (baseline n=239, follow-up n=295) at Monash Medical Centre (Beckman/Coulter, Sydney, Australia).
15 eGFR was estimated using the 're-expressed' Modification of Diet in Renal Disease (MDRD) study formula using calibrated serum creatinine values: eGFR (ml/min/1.73m
2 ) = 175 x ((serum creatinine (mg/dl)-1.154 ) x (age-0.203 ) x (0.742 if female)). 16 Change in eGFR was calculated as eGFR at follow-up minus eGFR at baseline and incident CKD was defined as an eGFR <60 ml/min/1.73 m 2 at follow-up.
17
Statistical analysis
For the present analyses we investigated individuals for whom full data were available at both baseline and follow-up and who did not have CKD or MA at baseline. Descriptive statistics are presented as mean ± standard deviation (SD), or in case of a skewed distribution as median (interquartile range) per tertile of PP, for individuals with and without type 2 diabetes separately. F tests for analysis of variance and T tests for comparing means in case of continuous variables, or Chi 2 tests in case of proportions were performed to test for differences between tertiles of PP and between individuals with and without type 2 diabetes. In case of skewed distributions, tests were done on log-transformed data.
Linear and logistic regression analyses were performed to assess the associations of PP, SBP and DBP with change in eGFR and incident CKD, for individuals with and without type 2 diabetes separately. To enable direct comparisons of the strength of associations with eGFR decline and incident CKD, all regression coefficients (ß) and OR's were reported per 1 SD increase in baseline PP (1 SD=14.2 mmHg), SBP (1 SD=17.8 mmHg) and DBP (1 SD=11.6 mmHg), with 95% confidence intervals (CI). Linearity of the models was checked using residual plots, and performing analyses stratified by tertiles of PP. To adjust for confounding, multivariable models were made including age, sex, baseline eGFR, and use of blood pressure lowering medication. Further potential confounding was investigated by adding mean arterial pressure, BMI, waist circumference, waisthip ratio, smoking, socio-economic status, cholesterol, triglyceride, or glucose levels, use of antihypertensive, or lipid or glucose lowering medication, prior CVD, heart rate, exercise time, and salt or alcohol intake one by one to the adjusted models.
All regression models were derived with either one or a combination of pressure measures (PP, SBP and/or DBP). We then investigated interactions between 2 pressure measures that were combined in an adjusted model by adding their product term to the model. In case of significant interaction (p<0.10) between 2 pressure measures, we further investigated this by showing associations of 1 pressure measure (the 1 that has the strongest association with eGFR decline) for subgroups (above/ below the mean) of the other pressure measure.
Except for the investigation of interactions (where p<0.10 was statistically significant), p values below 0.05 were considered statistically significant. Statistical analyses were performed with SPSS for Windows (version 15.0, SPSS Inc., Chicago, IL).
Of the 10,788 participants eligible for testing in [2004] [2005] 6 ,537 (60.6%) attended the follow-up examination. After exclusion of 216 individuals (3.3% of 6,537 follow-up participants) because of missing data and 767 individuals (12.1% of 6,321 with complete follow-up) with prevalent CKD and/ or MA at baseline, data from 5,554 individuals, 47% male, 5.8% with type 2 diabetes, aged 25-88 years were analysed. Those who attended the followup measurements were similar in age, DBP, and eGFR at baseline, but had lower baseline PP and SBP and were less likely to have type 2 diabetes as compared to non-attendees.
Individuals with type 2 diabetes commonly were older and had a worse CVD risk profile and renal function compared to individuals without type 2 diabetes (Table 3 .1). Similar differences existed between individuals with higher PP as compared to those with lower PP. Baseline eGFR was lower with higher PP, but not significantly within the group of individuals with type 2 diabetes. Individuals who had higher PP at baseline, had a lower eGFR, more pronounced eGFR decline and higher CKD incidence after 5 years of follow-up. Although incident CKD was only present in the highest tertile of PP within individuals with type 2 diabetes, eGFR was lower and CKD incidence was higher in individuals with type 2 diabetes as compared to those without type 2 diabetes.
Associations with eGFR decline
Mean baseline PP was 65.7 and 56.7 mmHg and mean eGFR decline after 5 years was 1.5 ± 8.5 and 1.4 ± 8.2 ml/min/1.72m 2 for individuals with and without type diabetes, respectively (Table 3. 2). The final regression model (Model 4) was adjusted for age, sex, baseline eGFR, and use of blood pressure lowering medication. Regression coefficients indicate the mean 5-year change in eGFR per SD higher baseline PP, SBP, or DBP. One SD higher PP was associated with a 5-year eGFR decline of 0.31 ml/min (95% CI: 0.07 to 0.54) in individuals without type 2 diabetes. In individuals with type 2 diabetes, 1 SD higher baseline PP was associated with a 1.10 ml/min (0.25 to 1.94) eGFR decline over a 5-year period (p for interaction by type 2 diabetes: 0.007). Adjusted models showed no association between DBP and decline in eGFR, and similar
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associations for SBP and PP with eGFR decline in individuals without type 2 diabetes. In individuals with type 2 diabetes, SBP and PP were both associated with an eGFR decline, but the magnitude of the association for SBP was smaller and not significant.
Interactions and additional analyses
In individuals with type 2 diabetes there was a significant interaction between DBP and SBP and eGFR decline and incident CKD in fully adjusted models. In these individuals, SBP was only significantly associated with eGFR decline and CKD if the DBP was below the median of 70 mmHg. One SD higher SBP was associated with a 1.89 ml/min (0.30 to 3.49) eGFR decline and with an OR of 14.5 (1.6 to 132.3) on CKD in individuals with a DBP ≤ 70 mmHg. In individuals who had a DBP > 70 mmHg, associations of SBP with eGFR decline (ß=0.40 (-0.79 to 1.58)) and CKD (OR=1.65 (0.8 to 3.4)) were not significant.
There were no significant interactions between age, sex, hypertension, or the use of blood pressure lowering medication and PP (p for interaction > 0.1) with eGFR decline or incident CKD. We repeated the analyses shown in Table 3 2 ) separately (data not shown). These analyses did, despite the lack of significance in some small subgroups, not materially alter our results. Furthermore, PP, SBP and DBP were not associated with incident MA or with changes in the ACR. We also investigated whether PP, SBP and DBP were associated with a combined outcome of incident CKD and/or MA. This resulted in similar, though slightly weaker results as compared to the associations shown with incident CKD only. Moreover, SBP seemed to be a slightly (although not significantly) stronger predictor as compared to PP of incident CKD and/or MA.
Data are reported as mean ± SD or median (interquartile range). T2DM=type 2 diabetes, PP=pulse pressure, SBP=systolic blood pressure, DBP=diastolic blood pressure, BMI=body mass index, eGFR=estimated glomerular filtration rate, ACR=albumin creatinine ratio, CKD=chronic kidney disease. *p < 0.05 for type 2 diabetes vs non-type 2 diabetes, † p<0.05 for tertile 1 vs 2, ‡ p<0.05 for tertile 2 vs 3, § p<0.05 for tertile 1 vs 3 
T2DM / nonT2DM
Mean eGFR decline ± SD Non-T2DM This study demonstrates that a higher baseline PP was associated with eGFR decline and incident CKD over a 5-year period, independent of age, sex and cardiovascular risk factors. These associations were stronger with the presence of type 2 diabetes. In individuals with type 2 diabetes, interaction between SBP and DBP indicated a favouring of PP over SBP in predicting an eGFR decline and/or incident CKD.
Our results support earlier findings that PP was associated with CVD and renal disease.
2;3;5;6;18; 19 The Hoorn Study has previously shown that in individuals with type 2 diabetes, pulse pressure significantly predicted cardiovascular mortality and systolic blood pressure did not. 7 The present paper showed that higher PP predicts eGFR decline and incident CKD in the general population as well, and that type 2 diabetes strengthens this PP-associated eGFR decline. Furthermore, we provide evidence to support the value of measuring PP over SBP in predicting CVD and CKD.
3;20;21 The interaction between SBP and DBP in predicting eGFR decline and CKD in individuals with type 2 diabetes, showed a higher SBP-associated risk with lower DBP. Since arterial stiffening causes elevation of SBP without elevation of DBP levels, thus widening PP, this finding might imply that arterial stiffening rather than an elevated blood pressure is the culprit in eGFR decline and CKD in type 2 diabetes.
22
PP may be regarded as an indirect measure of arterial stiffening, as the amplitude of pressure waves largely depend on 1) the high pressure induced with left ventricular ejection, 2) the cushioning capacity of arteries, which enables smoothing of flow pulsations to an almost steady stream through organs and tissues, and 3) wave reflections in peripheral branching of arteries.
4;22;23 Arterial stiffness is thought to cause vascular damage leading to deteriorating function of the kidneys and other organs through an increased mechanical strain and sheer stress, caused by this diminished pressure wave dampening.
18;20
In individuals without type 2 diabetes, there was no interaction between SBP and DBP and PP with eGFR decline. Furthermore, PP and SBP were very similarly associated with eGFR decline and incident CKD in these individuals. This confirms findings in the Physicians' Health Study that in a relatively healthy population, PP and SBP are equally strong predictors for the development of CKD.
9
ACR was higher with higher PP cross-sectionally (Table  3 .1), however we did not detect significant associations of any pressure variable with change in ACR or incident MA. Data from Palmas et al suggest that ambulant 24 hour PP measurement may better predict progression of MA than does PP as measured in the present study.
6
Strengths of this study include the large, prospective population based sample. The study also has some limitations. First, since no data were available on class of blood pressure lowering medicaDiscussion tion at baseline, we could not investigate the influence of different types of blood pressure lowering medication on PP, SBP, DBP, eGFR, and CKD. However, adjustment for the total use of blood pressure lowering medication did not change the associations. Furthermore, adjusting for follow up use of specific classes of blood pressure lowering medication (as a proxy) did not alter any of the reported results. Secondly, another important issue is the response rate at baseline (55.3%) and follow-up (60.6%).
12;13 Individuals who did not attend the follow-up examinations, had higher PP and SBP at baseline. It is possible that the differences between attendees and non-attendees suggests that a 'healthy cohort bias' may have occurred in this study, and this may have influenced our findings.
In the present study, we were unable to investigate whether the association of PP with renal function decline is really due to arterial stiffening. Although PP is an easy way to estimate arterial stiffness, there are better measurement methods, such as measuring distension parameters with arterial ultrasonography or pressure wave propagation and augmentation with pressure sensors.
21; 22 Other studies have shown that tonometry-derived pulse wave velocity or central PP were more strongly associated with CKD or eGFR than was brachial PP.
21; 24 The fact that we were able to detect associations with brachial PP might indicate an underestimation of the actual link between arterial stiffness and eGFR decline.
In conclusion, we report that a higher baseline PP is associated with eGFR decline and CKD incidence over a 5-year period in a population-based cohort, and that this is stronger in individuals with type 2 diabetes. This finding implies that the presence or absence of type 2 diabetes should be taken into account if PP is used to assess CKD risk. Moreover in individuals with diabetes, PP might better predict eGFR decline and incident CKD than does SBP, since a wide PP reflects the additive risk of having both high SBP and low DBP on eGFR decline and CKD. The increased amplitude of pressure waves due to arterial stiffness might further increase sheer stressassociated vascular damaging caused by high SBP. Prospective data including information on distension parameters with arterial ultrasonography and/or on pressure wave propagation and augmentation would be useful to determine whether arterial stiffness really explains the reported association of PP with eGFR decline and incident CKD. Nonetheless, PP was shown to be an easy to measure estimate of CKD risk which is especially applicable to assess CKD risk in individuals with type 2 diabetes.
